Phase II Trial of Adjuvant De-Escalated Radiation + Concurrent and Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer
Latest Information Update: 14 Dec 2023
At a glance
- Drugs Nivolumab (Primary)
- Indications Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 06 Dec 2023 Planned End Date changed from 30 Nov 2023 to 31 Mar 2024.
- 06 Jun 2023 Results (n=41) assessing the efficacy and safety of nivolumab in patients with intermediate-high risk P16+ oropharynx cancer, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 05 Jan 2023 Planned End Date changed from 30 Jun 2023 to 30 Nov 2023.